Coadministration of the prostaglandin F2α receptor antagonist preterm labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasone-Reference-Cited by-同舟云学术

Coadministration of the prostaglandin F2α receptor antagonist preterm labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasone

Published:2019-05-11 Issue:7 Volume:85 Page:1516-1527
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Pohl Oliver¹,Marchand Line¹,Gotteland Jean‐Pierre¹,Coates Simon²,Täubel Jörg²³,Lorch Ulrike²^ORCID

Affiliation:

1. ObsEva SA 1228 Plan‐les‐Ouates Switzerland

2. Richmond PharmacologySt. George's University London UK

3. St. George's University London UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.13925

Reference36 articles.

1. Born Too Soon: Preterm birth matters

2. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000

3. Preterm birth–associated neurodevelopmental impairment estimates at regional and global levels for 2010

4. The pharmacokinetics of the oxytocin antagonist atosiban in pregnant women with preterm uterine contractions

5. Pharmacokinetic interaction studies of atosiban with labetalol or betamethasone in healthy female volunteers

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preventing Preterm Birth;Clinics in Perinatology;2024-06

2. PGF2α induces a pro-labour phenotypical switch in human myometrial cells that can be inhibited with PGF2α receptor antagonists;Frontiers in Pharmacology;2023-12-14

3. Addressing a broken drug pipeline for preterm birth: why early preterm birth is an orphan disease;American Journal of Obstetrics and Gynecology;2023-12

4. Repurposing existing drugs as a therapeutic approach for the prevention of preterm birth;Reproduction;2023-01-01

5. Preterm Birth Therapies to Target Inflammation;The Journal of Clinical Pharmacology;2022-09